Meeting
2023 ASCO Annual Meeting
Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.
Authors
Gustavo Schvartsman
Hospital Israelita Albert Einstein, São Paulo, Brazil
Gustavo Schvartsman , Ana Carolina Pires de Rezende , Diogo Bugano Diniz Gomes , Ludmila De Oliveira Koch , Benoit Jacques Bibas , Oswaldo Gomes Jr., Paulo V Campregher , Patricia Severino , Luciana Cavalheiro Marti , Vitor Ribeiro Paes , Rodrigo Caruso Chate , José Milanez Ribas , Victor Aurelio Ramos Sousa , Patricia Taranto , Fernando Moura , Ricardo Mingarini Terra , Marcos Naoyuki Samano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04271384
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8554)
DOI
10.1200/JCO.2023.41.16_suppl.8554
Abstract #
8554
Poster Bd #
181
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.
First Author: Joe Y. Chang
Poster
2021 ASCO Annual Meeting
Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial.
First Author: Aasems Jacob
Poster
2021 ASCO Annual Meeting
Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.
First Author: Carlo Guerrero
Poster
2020 ASCO Virtual Scientific Program
I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.
First Author: Joe Y. Chang